Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 May-Jun;23(4-5):104811.
doi: 10.1016/j.micinf.2021.104811. Epub 2021 Mar 17.

COVID-19 vaccine decisions: considering the choices and opportunities

Peter J Hotez  1 , Tasmiah Nuzhath  2 , Timothy Callaghan  3 , Brian Colwell  2
Affiliations
Editorial

COVID-19 vaccine decisions: considering the choices and opportunities

Peter J Hotez et al. Microbes Infect. 2021 May-Jun.

Abstract

In the coming months, most American adults will have the opportunity to receive at least one of up to five different COVID-19 vaccines produced by Operation Warp Speed and released through emergency use authorization by the U.S. Food and Drug Administration (FDA). A similar group of vaccines will also be released in Europe by the European Medicines Agency (EMA) and in the United Kingdom by the Medicines & Healthcare products Regulatory Agency (MHRA). Those living outside of North America and Europe may not have access to those particular vaccines, but they will benefit from receiving vaccines produced in Brazil, China, India, or Russia. These vaccines and some of their major features based on clinical trials and testing are listed in Table 1 [1-25]. As vaccine scientists and policy experts working in the area of coronavirus disease 2019 (COVID-19), we are frequently asked about potential choices regarding the available vaccines, both in the U.S. and globally. Provided here is a summary and informal decision-making tool kit for considering the different vaccine options at this time.

Keywords: COVID-19; Vaccine distribution; Virus-neutralizing antibodies.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest PH is an inventor on a COVID-19 vaccine technology (recombinant protein vaccine) owned by Baylor College of Medicine that was recently licensed non-exclusively to Biological E Ltd., a commercial vaccine manufacturer for scale up, production, testing and licensure. No other authors have any conflicting interests to declare.

References

    1. Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–2615. https://www.nejm.org/doi/full/10.1056/NEJMoa2034577 - DOI - PMC - PubMed
    1. Liu Y., Liu J., Xia H., Zhang X., Fontes-Garfias C.R., Swanson K.A. Neutralizing activity of BNT162b2-elicited Serum—preliminary report. N Engl J Med. 2021 https://www.nejm.org/doi/full/10.1056/NEJMc2102017 - DOI - PMC - PubMed
    1. Chodcik G., Tene L., Patalon T., Gazit S., Ben-Tov A., Cohen D. The effectiveness of the first dose of BNT162 b 2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world evidence. Medrxiv. 2021 https://www.medrxiv.org/content/10.1101/2021.01.27.21250612v1.full-text - DOI - PMC - PubMed
    1. Hunter P.R., Brainard J.S. Estimating the effectiveness of the Pfizer COVID-19 BNT162b2 vaccine after a single dose. A reanalysis of a study of'real-world'vaccination outcomes from Israel. Medrxiv. 2021 https://www.medrxiv.org/content/10.1101/2021.02.01.21250957v1.full - DOI
    1. Mulligan M.J., Lyke K.E., Kitchin N., Absalon J., Gurtman A., Lockhart S. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586:589–593. https://www.nature.com/articles/s41586-020-2639-4 - PubMed

Publication types